Long-term Outcomes of Transcatheter Aortic Valve Replacement With the Lotus Valve vs CoreValve/EvolutR
David G. Rizik(Health Net), Michael J. Reardon(Houston Methodist), Matthias Götberg, Henrik Bjursten(Lund University), Gregory Mishkel(NorthShore University HealthSystem), Dominic J. Allocco(Boston Scientific (United States)), Axel Linke(Deutsches Herzzentrum der Charité), Vijay Iyer(Buffalo VA Medical Center), Neal S. Kleiman(Houston Methodist), Raj Makkar(Cedars-Sinai Medical Center), Tanvir Bajwa(Aurora Health Care), Maurice Buchbinder(Stanford University), Dean J. Kereiakes(Health Net), Vivek Rajagopal(Piedmont Atlanta Hospital), Ron Waksman(Clinical Research Institute), Robert Stoler(Baylor University Medical Center), Vinod H. Thourani(Valve (United States))
Cited by 6
Related Papers
Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery
|New England Journal of Medicine|2010|7.2k
Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk Patients
|New England Journal of Medicine|2011|6.4k
Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients
|New England Journal of Medicine|2016|5.1k
Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients
|New England Journal of Medicine|2019|4.8k
Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients
|New England Journal of Medicine|2019|3.6k